Community/Retail

With a cohort of approximately 50,000, this may be the largest exome sequencing study of type 2 diabetes.

Although recent trials for Merck's pembrolizumab injection demonstrated promise for recurrent or metastatic head and neck squamous cell carcinoma, testing for patients with metastatic triple-negative breast cancer did not meet the primary endpoint.

The survey looked into the participants’ confidence of specific approaches, including outcome-related measures, fee-for-service, intermediate outcome, and outcome-related measures.

The CDC has indicated that many recent measles cases reported in the United States in 2018 have been the result of international travel to areas of the world where the virus is active, and individuals who are not vaccinated against the virus.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The agency has opened a public docket to solicit feedback on the proposed requirement, which would necessitate certain immediate-release opioid analgesics be made available in fixed-quantity, unite-of-use blister packaging.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses what pharmacists bring to patient care in the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Patients must be counseled about the risk of acute or chronic liver steatosis associated with all prescription and over the counter medications.

The oral tablets under review by the FDA should be paired with rest, physical therapy and other measures, according to manufacturer Galt Pharmaceuticals.

The online program trains health care professionals in fundamentals of enteral and parenteral nutrition.

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses its medication access framework for quality measurement during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

The approval of R2 is based on data from the phase 3 AUGMENT study evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously-treated FL and MZL.

Effective treatment with ART has increased the life span of people living with HIV, but they remain at risk for chronic diseases.

The new indication makes cariprazine (Vraylar, Allergan and Gedeon Richter) the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes, according to the companies.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Uncontrolled diabetes in pregnancy can lead to preeclampsia, cesarean delivery, preterm delivery, significant overgrowth in the child, and congenital defects.

What is causing the visual distrubances in this young man?

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's origins as a measure developer during the PQA Annual Meeting in Baltimore, MD.

Ruxolitinib is the first and only FDA-approved treatment for this indication, according to Incyte, the drug's manufacturer.

Officials with the FDA have approved alpelisib (Piqray, Novartis) tablets, to be used in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and how they complement existing measures during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

The study included an analysis detailing crash and traffic violation records for newly licensed drivers. It is the first large-scale longitudinal study on this topic.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

PQA is described as a "a neutral convener of a multistakeholder base."

Understanding what constitutes a 'good' immune response to HIV may provide important information for vaccine design and intervention.

NKTR-181 is currently under review with the FDA, with a Prescription Drug User Fee Act (PDUFA) target action expected in August 2019.